an intranasal formulation of racemic ketamine. At JPM Week 2025 in San Francisco, pharmaphorum editor-in-chief Jonah Comstock met with Rick Stewart, CEO of Achieve Life Sciences.

Levocloperastine is a novel antitussive with a pharmacological profile distinct from that of the racemic DL-cloperastine. Levocloperastine with its dual mechanism of action acts on both the ...

In recent years, there has been particular interest in the antidepressant effects of ketamine in patients with TRD. Ketamine is a racemic mixture of two enantiomers, R- and S-ketamine, with the latter ...

The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...